|
SUNDAY,
SEPTEMBER 29, 2002 |
MONDAY,
SEPTEMBER 30, 2002 |
TUESDAY,
OCTOBER 1, 2002 |
WEDNESDAY,
OCTOBER 2, 2002 |
THURSDAY,
OCTOBER 3, 2002 |
| Orals |
Orals
|
Posters |
Orals
|
Posters |
Orals
|
Posters
|
Orals
|
Posters
|
| MONDAY, SEPTEMBER 30, 2002 |
| POSTER SESSION:
PATHOGENIC MECHANISMS |
| 1 |
aPL
IN PATIENTS WITH INTOLERANCE TO METALS IN THE ORAL CAVITY
H. Kucerova, J. Prochazkova, I. Janatkova, J. Bartova,
T. Fucikova, Czech Republic |
| 2 |
AUTOIMMUNE
aPL IMPAIR THE INHIBITION OF ACTIVATED FACTOR X BY PROTEIN
Z / PROTEIN Z DEPENDENT PROTEASE INHIBITOR
R.R. Forastiero, M.E. Martinuzzo, L.C. Kordich, G.J.
Broze, Argentina, USA |
| 3 |
DEVELOPMENT
OF aPL AND FACTOR V-INHIBITOR AFTER CIPROFLOXACIN IN TWO CASES
W. Miesbach, J. Vogt, D. Peez, B. Buehler, G. Asmelash,
I. Scharrer, Germany |
| 4 |
ANTICARDIOLIPIN
ANTIBODIES IN SERUM SAMPLES OF PATIENTS WITH CHRONIC HEPATITIS
C INFECTION
Z. Mondher, Z. Yusr, L. Lilia, A. Ilhem, S. Maryam, M.
Sondes, Tunisia |
| 5 |
CHARACTERIZATION
OF IMMUNOGLOBULIN-BOUND 'NATIVE' B2GPI FROM PLASMA (ISOLATED
UNDER MILD CONDITIONS)
B.L. Myones, S. Majumdar, L.I. Fedorova, J.D. Morrisett,
A.Y. Volgin, USA |
| 6 |
aPL
AFFECTS PROTEIN C ACTIVATION IN VIVO
S.S. Pierangeli, X. Liu, R.G. Espinola, E.N. Harris,
USA |
| 7 |
PATTERNS
OF THE PLATELET FUNCTION STATUS IN THE PATIENTS WITH APS
V.G. Karepov, Y. Levy, Y. Shoenfeld, Israel |
| |
| POSTER SESSION: ATHEROSCLEROSIS
AND APS |
| 8 |
THE
MEASUREMENT OF ANTI-CHOLESTEROL ANTIBODY SERUM LEVELS IN CHRONIC
HEPATITIS-C PATIENTS DURING IFN-ALPHA-2B TREATMENT
A. Biro, A. Horvath, L. Varga, E. Nemesanszky, A. Csepregi,
K. David, G. Tolvaj,
E. Ibranyi, L. Telegdy, A. Par, L. Romics, I. Karadi, A. Koles,
T. Balint, M. Horanyi,
Z. Prohaszka, G. Fust, Hungary |
| 9 |
THE
ROLE OF ANTIPHOSPHOLIPID ANTIBODY IN HEART DISEASES
A. Rafinejad, M. Hajiloui, S. Rafiei, Iran |
| 10 |
CLINICAL
SIGNIFICANCE OF SERUM OXIDIZED LDL IN PATIENTS WITH CHRONIC
RENAL DISEASE
J. Kasahara, K. Kobayashi, Y. Yamasaki, T. Yasuda,
T. Koike, H. Makino, E. Matsuura, Japan |
| 11 |
CORRELATION
BETWEEN B2GPI AND CRP LEVELS IN INFLAMMATION
F. Lin, C. Feighery, J. Jackson, Ireland |
| 12 |
INCREASED
LEVELS OF OXIDIZED-LDL IN SLE: DETECTION BY ELISA USING AN
ANTI-B2GP1 MONOCLONAL ANTIBODY
D. Lopez, K. Dier, C. Fink, K. Kobayashi, E. Matsuura, L.
Lopez, USA, Japan |
| 13 |
ANTIBODIES
AGAINST B2GPI AND CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS
PATIENTS
A. Durazinska, M. Szmyrka, B. Jazwiec, J. Szechinski,
Poland |
| 14 |
HOMOCYSTEINE
LEVELS AND aPL: IS THERE AN ASSOCIATION?
P.L. Casais, M.F. Alberto, M.J. Salviu, L.C. Gennari,
S.S. Meschengieser,
A.N. Blanco, M.A. Lazzari, Argentina |
| 15 |
FLUVASTATIN
INHIBITS INFLAMMATORY AND THROMBOGENIC PROPERTIES OF aPL IN
AN IN VIVO MODEL
D.E. Ferrara, X. Liu, R.G. Espinola, K. Labat, P.L.
Meroni, E.N. Harris, S.S. Pierangeli, USA, Italy |
| 16 |
aCL
TITER AND PLASMA HOMOCYSTEINE LEVEL ARE INDEPENDENT PREDICTORS
OF CAROTID INTIMA MEDIA THICKNESS IN PRIMARY APS
P.R.J. Ames, A. Margarita, J. Delgado Alvez, C. Tommasino,
L. Iannaccone,
V. Brancaccio, UK, Italy |
| 17 |
HOMOCYSTEINE
(HCY) AND THROMBOTIC RISK IN PATIENTS WITH aPLS
M.M. Martinuzzo, R.R. Forastiero, G.S. Cerrato, M.L.
Iglesias Varela, Y.P. Adamczuk,
L.O. Carreras, Argentina |
| 18 |
DO
ANTI-B2GPI AND ANTI-oxPAPC ANTIBODIES HAVE ANY ROLE IN THE
DEVELOPMENT OF ATHEROSCLEROSIS IN SLE?
A. Doria, A. Ghirardello, R. We, M. Puato, D. Bragagnolo,
B. Gilburd, E. Favaretto,
S. Zampieri, Y. Sherer, P. Pauletto, P.F. Gambari, Y. Shoenfeld,
USA, Israel |
| 19 |
ANTI-HIGH
DENSITY LIPOPROTEIN AND ANTI-B2GPI ANTIBODIES INVERSELY CORRELATE
WITH PARAOXONASE ACTIVITY AND TOTAL ANTIOXIDANT CAPACITY IN
PATIENTS WITH SLE AND APS
J. Delgado Alves, P.R.J. Ames, S. Donohue, J. Noorouz-Zadeh,
C.T. Ravirajan,
D.A. Isenberg, UK |
| 20 |
A
POSSIBLE PREDICTIVE ROLE FOR VASCULAR EVENTS OF APLA AND PLATELET
ACTIVATING FACTOR-ACETYL HYDROLAZE(PAF-AH) IN PATIENTS WITH
CORONARY DISEASE
C.M. Tanaseanu, E. Moldovean, T. Kosaka, S. Tanaseanu,
M. Popescu, Romania, Japan |
| |
| POSTER SESSION:
ENDOTHELIAL CELLS AND ANTI-ENDOTHELIAL CELL ANTIBODIES |
| 21 |
CERIVASTATIN
NEITHER INHIBITS THROMBIN GENERATION NOR DECREASES MARKERS
OF INFLAMMATION IN PATIENTS WITH APS
J. Musial, J. Swadzba, D. Rys, W. Sydor, T. Iwaniec,
Poland |
| 22 |
EFFECT
OF STATINS ON ENDOTHELIAL ACTIVATION BY TUMOR NECROSIS FACTOR
S. Dunoyer-Geindre, Y. Dimitrova, E. K. Kruithof, G.
Reber, P. de Moerloose, Switzerland |
| 23 |
IS
ANTI ENDOTHELIAL CELL ANTIBODY A SIGN OF APS IN IDDM ANGIOPATHY?
S. Rafiei, A. Rafinejad, N. Mosafa, Iran |
| 24 |
CIRCULATING
ENDOTHELIAL CELLS ARE A NOVEL MARKER OF ENDOTHELIAL DAMAGE
IN ANCA-ASSOCIATED SMALL-VESSEL VASCULITIS
A. Woywodt, F. Streiber, M. Schroeder, K. de Groot,
H. Haller, M. Haubitz, Germany |
| 25 |
PROBING
ANTIPHOSPHOLIPID – MEDIATED THROMBOSIS: THE INTERPLAY BETWEEN
ANTICARDIOLIPIN ANTIBODIES AND ENDOTHELIAL CELLS
S.S. Pierangeli, A.E. Gharavi, E.N. Harris, USA |
| 26 |
aPLS
ACTIVATE NUCLEAR FACTOR KAPPA B ON ENDOTHELIAL CELLS
S.S. Pierangeli, J.L. Hall, R.G. Espinola, D.E. Ferrara,
K. Roye-Green, E.N. Harris, USA, Jamaica |
| 27 |
ENDOTHELIAL
CELL DYSFUNCTION IN ANTIPHOSPHOLIPID SYNDROME (APS)
M.O. Borghi, E. Raschi, C. Testoni, C. Luzzana, M. Cugno,
D. Mari, A. Tincani,
P.L. Meroni, Italy |
| |
| POSTER SESSION: AUTO ANTIBODIES
IN APS |
| 28 |
PREVALENCE
OF ANTICARDIOLIPIN AND A-B2GPI ANTIBODIES IN GREEK PATIENTS WITH SLE
A. Pavlitou, V. Galanopoulou, A. Giannakou, R. Zilidou,
A. Fleva, G. Papaioannou,
M. Speletas, I. Griveas, D. Papadopoulou, G. Sakellariou,
Greece |
| 29 |
ANTIPHOSPHOLIPID
ANTIBODIES ARE NATURAL AUTOANTIBODIES PLUS HISTONES
D.N. Abakushin, A.M. Poverenny, Russia |
| 30 |
LUPUS
ANTICOAGULANT QUANTIFICATION IN HEPARINIZED PATIENTS USING ADDITION OF POLYBRENE
E.M. Jacobsen, E.J. Trettenes, F.G. Strekerud, F. Wisloff,
U. Abildgaard, Norway |
| 31 |
THE
INFLUENCE OF CALCIUM IONS ON THE DETECTION OF ANTI-ANNEXIN V ANTIBODIES
N. Gaspersic, T. Kveder, B. Rozman, B. Bozic, Slovenia |
| 32 |
LINK
BETWEEN ANTI-CD36 ANTIBODIES AND THROMBOSIS IN THE APS
Y. Pelegri, G. Cerrato, R. Forastiero, M. Martinuzzo,
L.O. Carreras, Argentina |
| 33 |
ANTIPHOSPHATIDYLATHANOLAMINE
ANTIBODIES IN SLE PATIENTS AND PRIMARY APS PATIENTS
T.M. Reshetnyak, B. Wojciechowska, Y. Zabek, E.S. Mach,
Z.S. Alekberova,
V.A. Nassonova, Russia, Poland |
| 34 |
THE
VALUE OF ANTI-B2-GP1 IN SLE PATIENTS
S. Sokolovic, M. Seremet, Bosnia Herzegovina |
| 35 |
ASSOCIATION
OF AUTOANTIBODIES AGAINST THE PHOSPHATIDYLSERINE-PROTHROMBIN COMPLEX WITH
APS
D. Pascual-Salcedo, E.M. Delgado, F. Arribas, M.V.
Cuesta, R. Madero,
M.F.G. Iglesias, A. Gil Aguado, Spain |
| 36 |
AUTOANTIBODIES
AGAINST PHOSPHOLIPID PROFILE IN PATIENTS WITH SLE
C. Andrys, M. Drahosova, Czech Republic |
| 37 |
CLINICAL
SIGNIFICANCE OF ANTI-PHOSPHATIDYLSERINE/PROTHROMBIN (PS/PT) COMPLEX ANTIBODIES
IN PATIENTS WITH SLE
J. Kaburaki, M. Kuwana, Y. Ikeda, Japan |
| |
| POSTER SESSION: CLINICAL
MANIFESTATIONS AND ASSOCIATION |
| 38 |
APS
AND ITS CLINICAL MANIFESTATIONS
Z. Macejova, J. Szilasiova, D. Trejbal, Slovak Republic |
| 39 |
APS
IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
A.E. Dorofeyev, Ukraine |
| 40 |
aPL
AND HEPARIN INDUCED THROMBOCYTOPENIA TYPE II (HIT) IN CHRONIC THROMBOEMBOLIC
PULMONARY HYPERTENSION
C. Colorio, R. Forastiero, M. Martinuzzo, A. Macchia,
G. Pombo, D. Puente, A. Rossi,
L. Carreras, Argentina |
| 41 |
MAGIC
SYNDROME AND aPLS
C.C. Belizna, B. Faller, P. Brignon, France |
| 42 |
ANTICARDIOLIPIN
ANTIBODIES AND STILL DISEASE
C.C. Belizna, M.A. Pistorius, B. Planchon, France |
| 43 |
SOLUBLE
ADHESION MOLECULES IN SLE PATIENTS WITH/WITHOUT aPLS
D.V. Reshetnyak, E.N. Alexandrova, A.A. Novikov, T.M.
Reshetnyak, N.G. Kljukvina, M.U. Samsonov, E.L. Nassonov,
Russia |
| 44 |
DIFFUSE
PULMONARY HEMORRHAGE IN APS: IMPORTANCE OF ANTICOAGULATION
M. Silverberg, D. Erkan, M.D. Lockshin, USA |
| 45 |
HAEMOLYTIC-UREMIC
SYNDROME IN A PATIENT WITH APS AND AUTOIMMUNE HEPATITIS
E. Nomikou, G. Theodossiades, P. Raphailidis, K. Maragos,
M. Bellia, S. Katsudas,
E. Digenopoulou, I. Kontopoulou-Griva, S. Dourakis, Greece |
| 46 |
APS
IS A MAJOR CAUSE OF CHRONIC DAMAGE IN PATIENTS WITH SLE
J. Ugalde, V. Egurbide, G. Ruiz-Irastorza, C. Aguirre,
Spain |
| 47 |
ANTIPHOSPHOLIPID
THROMBOSIS SYNDROME (APS)
M. Hulikova, Slovak Republic |
| 48 |
APS
- THE EFFECT OF THE PENDULUM
M.P. Baleva, K.V. Nikolov, Bulgaria |
| 49 |
THE
ALTERATION OF PLATELET FUNCTION IN APS
O.M. Serbic, I.V. Elezovic, V.B. Lazarevic, N.D. Suvajdzic,
Yugoslavia |
| 50 |
BLEEDING
SYMPTOMS IN PATIENTS WITH APS
W. Miesbach, B. Buehler, G. Asmelash, I. Scharrer, Germany |
| 51 |
aPLS
ASSOCIATED WITH HEMORRHAGIA RATHER THAN THROMBOSIS: A CASE REPORT
Z. Mondher, C.R. Rim, S. Maryam, M. Sondes, Tunisia |
| 52 |
THROMBOTIC
EVENTS IN PATIENTS WITH APS, SLE AND RELATED DISEASES
L. Diez Porres, A. Gil Aguado, P. Lavilla, D. Pascual,
M.V. Cuesta, J.I. Bernardino,
M. Mora, T. Cobo, F. Gaya, Spain |
| 53 |
aPL
TITERS IN PATIENTS WITH SUCCESSFUL RENAL TRANSPLANTS
S. Vaidya, J. Daller, K. Gugliuzza, USA |
| 54 |
ANTICARDIOLIPIN
AND A-B2GPI ANTIBODIES IN MONOCLONAL GAMMOPATHIES
S. Ramos, G. Bierfass, G. Carballo, F. Ingenito, N.
Coraggio, A.M. Di Lonardo, Argentina |
| 55 |
SLE
AND ACQUIRED INHIBITOR OF THE FACTOR VIII
D.S. Fernanez Romero, U.J. Scher, M.V. Paolini, M.E.
Prada, G. Bierfass,
A.M. Di Lonardo, Argentina |
| 56 |
SEX
RATIO OF RHEUMATIC DISEASE
M.D. Lockshin, USA |
| 57 |
OCCURRENCE
OF ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH INCREASED LEVELS OF SERUM
IgM AND NON-SPECIFIC CLINICAL SYMPTOMS. PRELIMINARY REPORT
D. Jilek, V. Kral, I. Stiborova, J. Richter, Czech
Republic |
| |
| POSTER SESSION: DIAGNOSTICS |
| 58 |
POLYARTERITIS
WITH ANTICARDIOLIPIN ANTIBODIES
M.L. Ciompi, A. Delle Sedie, Italy |
| 59 |
DOES
SUBCUTANEOUS ADMINISTRATION OF LOW MOLECULAR WEIGHT HEPARIN CAUSE FALSE
POSITIVE TESTS FOR LUPUS ANTICOAGULANT?
S. Liestoel, F. Wisloff, Norway |
| 60 |
CAN
TRANSIENT aCL-IGM BE THE ONLY MARKER OF A PREVIOUS THROMBOTIC EVENT?
W. Miesbach, B. Buehler, G. Asmelash, I. Scharrer, Germany |
| |
|
| POSTER SESSION: SCREENING |
| 61 |
DIVERSITY
OF SO-CALLED aPLS IN PATIENTS WITH SLE AND RELATED DISORDERS
J. Kaburaki, T. Sugi, S. Goto, J. Okada, M. Nakamura,
T. Makino, Japan |
| 62 |
SERUM
LEVELS OF aCL AND DISEASE ACTIVITY IN SLE
I.M.Manolova , M.M. Dancheva, M.I. Ivanova, K.S.
Halacheva, Bulgaria |
| 63 |
THE
SIGNIFICANCE OF SUSTAINED ELEVATED
A-B2GPI ANTIBODIES AND THEIR RELATIONSHIP WITH APS
K. Hampton, S. Kitchen, L. Williams, C. Brookfield, UK |
| 64 |
CLINICAL
CORRELATIONS BETWEEN A-B2GPI AND aCL IN 78 PATIENTS
A. Bondanza, M. Iannacone, G. Ciboddo, S. Panza, E.
Baldissera, L. Praderio, R. Ieri, M.G. Sabbadini, Italy |
| 65 |
THE
PERSISTENCE OF aCLs OVER TIME IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF
THE PRESENCE OF LUPUS ANTICOAGULANT OR A-B2GPI ANTIBODIES
P.R. Fortin, J. Kassis, C. Neville, E. Chang, L. Joseph,
J. Rauch, Canada |
| 66 |
aPLS
AT THE TIME OF DIAGNOSIS OF SLE ARE A PERSISTENT MARKER OF DISEASE SEVERITY
J. Ugalde, V. Egurbide, G. Ruiz-Irastorza, C. Aguirre,
Spain |
| 67 |
IgG
aCLs TITER IS STRONGLY ASSOCIATED WITH NEW THROMBOEMBOLIC EPISODES IN PRIMARY
APS: A FIVE-YEAR PROSPECTIVE STUDY
F. Atzeni, P. Sarzi-Puttini, E. Rossi, M. Turiel, S.
Muzzupappa, Italy |
|
| POSTER SESSION: CRITERIA |
| 68 |
VALIDATION
OF SAPPORO CRITERIA IN APS PATIENTS WITH aCL/LAC POSITIVITY VS. OTHER SEROLOGIC
SUBSETS
G.A. McCarty, T.E. Cason, USA |
SUNDAY,
SEPTEMBER 29, 2002 |
MONDAY,
SEPTEMBER 30, 2002 |
TUESDAY,
OCTOBER 1, 2002 |
WEDNESDAY,
OCTOBER 2, 2002 |
THURSDAY,
OCTOBER 3, 2002 |
| Orals |
Orals
|
Posters |
Orals
|
Posters |
Orals
|
Posters
|
Orals
|
Posters
|
|
|
